Occult hepatitis B infection reactivation after ruxolitinib therapy

Dig Liver Dis. 2017 Jun;49(6):719. doi: 10.1016/j.dld.2017.03.004. Epub 2017 Mar 18.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antiviral Agents / therapeutic use
  • Drug Resistance
  • Enzyme Inhibitors / therapeutic use
  • Guanine / analogs & derivatives
  • Guanine / therapeutic use
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / etiology*
  • Humans
  • Hydroxyurea / therapeutic use
  • Janus Kinase Inhibitors / adverse effects*
  • Male
  • Middle Aged
  • Nitriles
  • Polycythemia Vera / complications
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / etiology
  • Pyrazoles / adverse effects*
  • Pyrimidines
  • Tenofovir / therapeutic use
  • Virus Activation*

Substances

  • Antiviral Agents
  • Enzyme Inhibitors
  • Janus Kinase Inhibitors
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • entecavir
  • Guanine
  • ruxolitinib
  • Tenofovir
  • Hydroxyurea